Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SS) on Thursday said it has entered into a licensing and commercialization agreement with a strategic partner in Malaysia for its denosumab biosimilars MAILISHU and MAIWEIJIAN.
Under the agreement, the partner will handle registration and commercialization in Malaysia, while Mabwell will be responsible for development, manufacturing and supply of the products.
MAILISHU, a biosimilar of Amgen's Prolia, has been approved by National Medical Products Administration (NMPA) for the treatment of postmenopausal osteoporosis, while MAIWEIJIAN, a biosimilar of Amgen's Xgeva, has been approved by the NMPA for giant cell tumor of the bone.
"Malaysia has an internationally aligned regulatory environment, strong regional recognition and significant space for development. This collaboration will further deepen Mabwell's presence in the ASEAN market. We look forward to rapidly advancing the product's local registration and commercialization with our partner's strong commercial capabilities, bring high-quality, affordable treatment options to more patients in the region," Huiguo Hu, Board Member, Senior Vice President and Board Secretary of Mabwell, said.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.